Form 4: Xencor Insider Acquires Shares, Options Granted

Xencor Inc. reports a Form 4 filing detailing insider Kevin Charles Gorman's acquisition of restricted stock units and stock options.

Summary

• Kevin Charles Gorman, a director at Xencor Inc., acquired 10,302 shares of common stock on June 16, 2026, with no cost indicated.
• Additionally, Gorman was granted a stock option to purchase 20,604 shares of common stock, exercisable at $12.20 per share.
• The restricted stock units are set to fully vest on the first anniversary of the grant date.
• The stock options will vest in equal monthly installments over one year, starting one month after June 16, 2026, with full vesting by June 16, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine insider transactions and compensation grants rather than significant strategic or financial events.

Positives

• Insider acquisition of shares and options can signal confidence in the company's future prospects.
• The grant of stock options provides potential upside for management aligned with shareholder value.
• Restricted stock units and options are structured with vesting schedules, encouraging long-term commitment.

Negatives

• The filing does not provide details on the specific reasons for the acquisition or grant, such as performance-based incentives or compensation adjustments.
• The exercise price of the stock options ($12.20) is higher than the current market price, suggesting that the options may not be immediately in-the-money.

Risks

• Vesting schedules for stock options and restricted stock units are subject to continued employment, meaning a departure before vesting would result in forfeiture.
• The value of the stock options is contingent on the future performance of Xencor's stock price.

Future Outlook

The vesting schedules for both restricted stock units and stock options indicate a forward-looking incentive structure tied to continued employment and company performance over the next one to two years.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The grant of stock options and restricted stock units to directors is a common practice in the biotechnology and pharmaceutical sectors to align executive compensation with long-term company value and shareholder interests.

Stakeholder Impact

• Shareholders: The acquisition of shares by a director may be viewed positively, suggesting insider confidence. The stock options, if exercised profitably, could lead to increased dilution in the future.
• Employees: The vesting schedules for the options and RSUs incentivize continued employment and performance.
• Management: The grants are part of the compensation structure for key personnel.

Next Steps

• Vesting of restricted stock units on the first anniversary of the grant date.
• Monthly vesting of stock options over one year, commencing one month after the grant date, with full vesting by June 16, 2027.

Key Dates

Keywords

Xencor, XNCR, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Beneficial Ownership, Securities Exchange Act, Kevin Charles Gorman, Director